- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Aptorum Group Ltd Class A (NIKI)
Aptorum Group Ltd Class A stock price live, this page displays NASDAQ NIKI stock exchange data. View the NIKI premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Aptorum Group Ltd Class A real time stock price chart below.
What Is the Aptorum Group Ltd Class A Stock Price Today?
The Aptorum Group Ltd Class A stock price today is 8.990.
What Is the Stock Symbol for Aptorum Group Ltd Class A?
The stock symbol for Aptorum Group Ltd Class A is "NIKI."
What Stock Exchange Does Aptorum Group Ltd Class A Trade On?
Aptorum Group Ltd Class A is listed and trades on the NASDAQ stock exchange.
Is Aptorum Group Ltd Class A a Good Stock to Buy?
Determining whether Aptorum Group Ltd Class A—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NIKI quote. (ISIN: US6539421023)
What Is the Aptorum Group Ltd Class A Stock Price Today?
The Aptorum Group Ltd Class A stock price today is 8.990.
What Is the Stock Symbol for Aptorum Group Ltd Class A?
The stock symbol for Aptorum Group Ltd Class A is "NIKI."
What Stock Exchange Does Aptorum Group Ltd Class A Trade On?
Aptorum Group Ltd Class A is listed and trades on the NASDAQ stock exchange.
Is Aptorum Group Ltd Class A a Good Stock to Buy?
Determining whether Aptorum Group Ltd Class A—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NIKI quote. (ISIN: US6539421023)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
8.780
9.270
52 wk Range
6.000
44.700
NIKI is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
8.7809.270
52 wk Range
6.00044.700
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NIKI Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock has taken a big hit over the last week
Form 6K Aptorum Group Ltd Class A For: 10 June- Investing.com
Form 6K Aptorum Group Ltd For: 22 June- Investing.com
- Form 6K Aptorum Group Ltd For: 22 June
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral
Aptorum Group Ltd Class A Earnings Call Summary for Q4/2024
- Record Q4 2024 revenue of $254M, net income of $19.2M ($0.12/share), and adjusted EBITDA of $62.9M
- Stock declined 3.13% in last session; 90% drop over past year but 2.75% gain in past week
- 2025 gold equivalent production guidance: 102,900-117,200 ounces; CapEx forecast: $28.2M-$32M
- Successful integration of Golden Queen, doubling company size in revenue and production
- Focus on operational efficiencies, exploration, and inorganic growth opportunities for 2025
Last Updated: 2025-03-19, 10:04 a/m
Read Full TranscriptEarnings
Latest Release
Mar 27, 2026
EPS / Forecast
-0.04 / --
Revenue / Forecast
-- / --
Compare NIKI to Peers and Sector
Metrics to compare | NIKI | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNIKIPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.4x | −1.7x | −0.4x | |
PEG Ratio | −0.07 | 0.03 | 0.00 | |
Price/Book | 0.3x | 3.0x | 2.6x | |
Price / LTM Sales | - | 4.8x | 3.0x | |
Upside (Analyst Target) | - | 136.4% | 48.7% | |
Fair Value Upside | Unlock | 0.5% | 5.6% | Unlock |
Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in a Phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa. The company also develops SACT-COV19, a repurposed small molecule, which is in a preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule, which is in a preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule, which is in a preclinical trial for the treatment of gram+ve bacterial infections. The company was formerly known as Aptorum Group Limited and changed its name to Niki BioSolutions, Inc. in July 2026. Niki BioSolutions, Inc. was incorporated in 2010 and is headquartered in Princeton, New Jersey. Niki BioSolutions, Inc. operates as a subsidiary of Jurchen Investment Corporation.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Aptorum A (NIKI) Stock Price Today?
The Aptorum A stock price today is 8.990 USD.
What Stock Exchange Does Aptorum A Trade On?
Aptorum A is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Aptorum A?
The stock symbol for Aptorum A is "NIKI."
What Is the Aptorum A Market Cap?
As of today, Aptorum A market cap is 7.570M USD.
What Is Aptorum A's Earnings Per Share (TTM)?
The Aptorum A EPS (TTM) is -1.854.
From a Technical Analysis Perspective, Is NIKI a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Aptorum A Stock Split?
Aptorum A has split 2 times.
What is the current trading status of Aptorum A (NIKI)?
As of Aug 08, 2026, Aptorum A (NIKI) is trading at a price of 8.990 USD, with a previous close of 9.290 USD. The stock has fluctuated within a day range of 8.780 USD to 9.270 USD, while its 52-week range spans from 6.000 USD to 44.700 USD.
What Is the NIKI Premarket Price?
NIKI's last pre-market stock price is 8.920 USD. The pre-market share volume is 350.000, and the stock has decreased by -0.370, or -3.980%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.